Marchioni Michele, Bandini Marco, Pompe Raisa S, Martel Tristan, Tian Zhe, Shariat Shahrokh F, Kapoor Anil, Cindolo Luca, Briganti Alberto, Schips Luigi, Capitanio Umberto, Karakiewicz Pierre I
Department of Urology, SS Annunziata Hospital, 'G. D'Annunzio' University of Chieti, Chieti, Italy.
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
BJU Int. 2018 Mar;121(3):383-392. doi: 10.1111/bju.14024. Epub 2017 Oct 12.
To assess the effect of lymph node dissection (LND), number of removed nodes (NRN), and number of positive nodes (NPN), on cancer-specific mortality (CSM) in contemporary vs historical patients with pT N M renal cell carcinoma (RCC) treated with radical nephrectomy (RN).
Within the Surveillance, Epidemiology, and End Results database (2001-2013), we identified patients with non-metastatic pT N RCC who underwent RN with or without LND. Kaplan-Meier analyses and multivariable Cox regression models with propensity score weighting for inverse probability of treatment were used.
Of 25 357 patients, 24.8% underwent LND (2001-2007: 3 167 patients vs 2008-2013: 3 133 patients). The median NRN was 3 (interquartile range [IQR]: 1-7). Positive nodes were identified in 17.1%: 9.3% of pT and 21.6% of pT patients, who underwent LND. The median NPN was 2 (IQR: 1-3). In multivariable models, LND did not decrease CSM (hazard ratio [HR] 1.29; P < 0.001). LND extent, defined as NRN, did not decrease CSM (HR 0.94; P = 0.3). Finally, multivariable models testing the effect of NPN showed increased CSM in pT but not in pT patients (HR 1.29 and 1.58, P = 0.02 and P = 0.1, respectively). NRN exerted a protective effect on CSM in patients with positive nodes (HR 0.98; P = 0.007).
In contemporary and historical patients LND or its extent do not protect from CSM. However, the NPN increases the rate of CSM in pT patients. Consequently, LND and its extent appear to have little if any therapeutic value in pT N M patients, besides its prognostic impact. High-risk non-metastatic patients may represent a target population for a multi-institutional prospective trial.
评估淋巴结清扫术(LND)、切除淋巴结数量(NRN)及阳性淋巴结数量(NPN)对接受根治性肾切除术(RN)治疗的当代及历史时期pT N M期肾细胞癌(RCC)患者癌症特异性死亡率(CSM)的影响。
在监测、流行病学与最终结果数据库(2001 - 2013年)中,我们识别出接受了有或无LND的RN治疗的非转移性pT N RCC患者。采用Kaplan - Meier分析以及带有倾向评分加权的多变量Cox回归模型来处理治疗的逆概率。
在25357例患者中,24.8%接受了LND(2001 - 2007年:3167例患者,2008 - 2013年:3133例患者)。NRN的中位数为3(四分位间距[IQR]:1 - 7)。17.1%的患者发现有阳性淋巴结:接受LND的pT患者中为9.3%,pT患者中为21.6%。NPN的中位数为2(IQR:1 - 3)。在多变量模型中,LND并未降低CSM(风险比[HR] 1.29;P < 0.001)。以NRN定义的LND范围也未降低CSM(HR 0.94;P = 0.3)。最后,测试NPN影响的多变量模型显示,pT患者的CSM升高,但pT患者未升高(HR分别为1.29和1.58,P分别为0.02和0.1)。NRN对有阳性淋巴结的患者的CSM有保护作用(HR 0.98;P = 0.007)。
在当代及历史时期患者中,LND或其范围并不能预防CSM。然而,NPN会增加pT患者的CSM发生率。因此,除了其预后影响外,LND及其范围在pT N M患者中似乎几乎没有治疗价值。高危非转移性患者可能是多机构前瞻性试验的目标人群。